Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a hold rating to a sell rating in a research note issued to investors on Tuesday.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $1.21 on Tuesday. Brainstorm Cell Therapeutics has a 12 month low of $1.05 and a 12 month high of $11.89. The stock has a market cap of $6.44 million, a P/E ratio of -0.35 and a beta of 0.40. The stock’s 50 day moving average price is $2.53 and its 200 day moving average price is $4.71.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60). During the same period in the prior year, the business earned ($4.05) EPS. Equities analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 EPS for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.